glp-1 agonist weight gain effects Psychological and behavioral of and GIP agonists in loss: a comprehensive review | Journal of Diabetes & Metabolic Disorders GLP-1 Agonists - What is

Qiao Q, Ouwens MJ, Grandy S, Johnsson K, Kostev K

The additional glucagon receptor activation from retatrutide could break through this plateau by adding increased energy expenditure to the equation

Long-Term Data Is Not Available These medications are newer and without long-term data

Because weight loss is rapid, users often lose a significant amount of muscle mass

Vincent's, says she's excited to offer patients an oral GLP-1 receptor agonist with no food or water restrictions, since choice matters when committing to a medication for months or years

The intensive treatment of the multiple risk factors reduces the development/progression of renal disease18 which is why guidelines insist on comprehensive management of the patient with diabetes (glycemic control and control of cardiovascular risk factors, use of renin-angiotensin system inhibitors, as well as lifestyle changes, including smoking cessation or weight loss in overweight/obese individuals, among others).19 However, the residual renal risk remains very high in optimally treated patients.20 More recently, iSGLT2 has been shown to reduce the risk of cardiovascular and renal events, but still, the residual risk of renal disease progression remains high.21,22 Nevertheless, although the rate of diabetes-related complications (such as myocardial infarction, stroke, lower limb amputations or mortality) have decreased significantly in recent decades, this is not the same for CKD patients requiring renal replacement therapy attributed to diabetic kidney disease (DKD).23 Therefore new treatments are needed that improve glycemic control independently of GFR, with a low risk of hypoglycemia and able to reduce cardiovascular and renal risk in this population